{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:38:07Z","timestamp":1771677487154,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"DOI":"10.7759\/cureus.20330","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T17:59:15Z","timestamp":1639159155000},"source":"Crossref","is-referenced-by-count":4,"title":["Dasatinib-Induced Nephrotic Syndrome: A Case Report"],"prefix":"10.7759","author":[{"given":"Ahmed","family":"ElShaer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazen","family":"Almasry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"Alawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Masoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Rahman","family":"El Kinge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21395","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel RL","year":"2017","unstructured":"Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017, 67:177-93. 10.3322\/caac.21395","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Goldman JM","year":"2001","unstructured":"Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344:1084-6. 10.1056\/NEJM200104053441409","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker BJ","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, et al.. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006, 355:2408-17. 10.1056\/NEJMoa062867","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford S","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, et al.. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003, 102:276-83. 10.1182\/blood-2002-09-2896","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701665988","article-title":"Strategies for overcoming imatinib resistance in chronic myeloid leukemia","volume":"48","author":"Kujawski L","year":"2007","unstructured":"Kujawski L, Talpaz M. Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymphoma. 2007, 48:2310-22. 10.1080\/10428190701665988","journal-title":"Leuk Lymphoma"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson RA","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, et al.. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012, 26:2197-203. 10.1038\/leu.2012.134","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian HM","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, et al.. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012, 119:1123-9. 10.1182\/blood-2011-08-376087","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0056-z","article-title":"Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML)","volume":"28","author":"Abruzzese E","year":"2014","unstructured":"Abruzzese E, Breccia M, Latagliata R. Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML). BioDrugs. 2014, 28:17-26. 10.1007\/s40259-013-0056-z","journal-title":"BioDrugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour E","year":"2015","unstructured":"Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015, 15:323-34. 10.1016\/j.clml.2015.03.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref10","article-title":"Nephrotic proteinuria developed under dasatinib treatment in a patient with chronic myeloid leukemia: a case report and review of the literature","volume":"3","author":"De Luca M","year":"2016","unstructured":"De Luca M, Carmosino I, Stefanizzi C, et al.. Nephrotic proteinuria developed under dasatinib treatment in a patient with chronic myeloid leukemia: a case report and review of the literature. Ann Hematol Oncol. 2016, 3:1106.","journal-title":"Ann Hematol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-013-2696-0","article-title":"Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature","volume":"29","author":"Ruebner RL","year":"2014","unstructured":"Ruebner RL, Copelovitch L, Evageliou NF, Denburg MR, Belasco JB, Kaplan BS. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol. 2014, 29:863-9. 10.1007\/s00467-013-2696-0","journal-title":"Pediatr Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.025932","article-title":"Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways","volume":"37","author":"Li X","year":"2009","unstructured":"Li X, He Y, Ruiz CH, Koenig M, Cameron MD, Vojkovsky T. Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos. 2009, 37:1242-50. 10.1124\/dmd.108.025932","journal-title":"Drug Metab Dispos"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0224","article-title":"Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors","volume":"15","author":"Demetri GD","year":"2009","unstructured":"Demetri GD, Lo Russo P, MacPherson IR, et al.. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009, 15:6232-40. 10.1158\/1078-0432.CCR-09-0224","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.01.022","article-title":"Dasatinib-induced nephrotic-range proteinuria","volume":"61","author":"Wallace E","year":"2013","unstructured":"Wallace E, Lyndon W, Chumley P, Jaimes EA, Fatima H. Dasatinib-induced nephrotic-range proteinuria. Am J Kidney Dis. 2013, 61:1026-31. 10.1053\/j.ajkd.2013.01.022","journal-title":"Am J Kidney Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1273-6","article-title":"Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report","volume":"20","author":"Ochiai S","year":"2019","unstructured":"Ochiai S, Sato Y, Minakawa A, Fukuda A, Fujimoto S. Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report. BMC Nephrol. 2019, 20:87. 10.1186\/s12882-019-1273-6","journal-title":"BMC Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-020-00484-8","article-title":"A case of long-term dasatinib-induced proteinuria and glomerular injury","volume":"9","author":"Koinuma K","year":"2020","unstructured":"Koinuma K, Sakairi T, Watanabe Y, et al.. A case of long-term dasatinib-induced proteinuria and glomerular injury. CEN Case Rep. 2020, 9:359-64. 10.1007\/s13730-020-00484-8","journal-title":"CEN Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144878","article-title":"Nephrotoxicity associated with novel anticancer agents (aflibercept, dasatinib, nivolumab): case series and nephrological considerations","volume":"21","author":"Piscitani L","year":"2020","unstructured":"Piscitani L, Sirolli V, Di Liberato L, Morroni M, Bonomini M. Nephrotoxicity associated with novel anticancer agents (aflibercept, dasatinib, nivolumab): case series and nephrological considerations. Int J Mol Sci. 2020, 21: 4878. 10.3390\/ijms21144878","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2020.100211","article-title":"BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon","volume":"14","author":"Stanchina M","year":"2020","unstructured":"Stanchina M, McKinnell Z, Park JH, Stein EM, Cai SF, Taylor J. BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon. Leuk Res Rep. 2020, 14:100211. 10.1016\/j.lrr.2020.100211","journal-title":"Leuk Res Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2019.60.250","article-title":"Dasatinib-induced nephrotic syndrome: a case of phenoconversion","volume":"60","author":"Mandac Rogulj I","year":"2019","unstructured":"Mandac Rogulj I, Mati\u0161i\u0107 V, Arsov B, Boban L, Juginovi\u0107 A, Molnar V, Primorac D. Dasatinib-induced nephrotic syndrome: a case of phenoconversion. Croat Med J. 2019, 60:250-4. 10.3325\/cmj.2019.60.250","journal-title":"Croat Med J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina V","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, et al.. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008, 358:1129-36. 10.1056\/NEJMoa0707330","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.241620","article-title":"Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes","volume":"286","author":"Bertuccio C","year":"2011","unstructured":"Bertuccio C, Veron D, Aggarwal PK, Holzman L, Tufro A. Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J Biol Chem. 2011, 286:39933-44. 10.1074\/jbc.M111.241620","journal-title":"J Biol Chem"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.13.1.513","article-title":"Cellular functions regulated by Src family kinases","volume":"13","author":"Thomas SM","year":"1997","unstructured":"Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997, 13:513-609. 10.1146\/annurev.cellbio.13.1.513","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S35360","article-title":"Systematic review of dasatinib in chronic myeloid leukemia","volume":"6","author":"Breccia M","year":"2013","unstructured":"Breccia M, Salaroli A, Molica M, Alimena G. Systematic review of dasatinib in chronic myeloid leukemia. Onco Targets Ther. 2013, 6:257-65. 10.2147\/OTT.S35360","journal-title":"Onco Targets Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60070","article-title":"Crk1\/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease","volume":"122","author":"George B","year":"2012","unstructured":"George B, Verma R, Soofi AA, et al.. Crk1\/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease. J Clin Invest. 2012, 122:674-92. 10.1172\/JCI60070","journal-title":"J Clin Invest"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010111158","article-title":"Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease","volume":"22","author":"Iyoda M","year":"2011","unstructured":"Iyoda M, Shibata T, Hirai Y, Kuno Y, Akizawa T. Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. J Am Soc Nephrol. 2011, 22:1486-96. 10.1681\/ASN.2010111158","journal-title":"J Am Soc Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/79172-dasatinib-induced-nephrotic-syndrome-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:11Z","timestamp":1707507191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/79172-dasatinib-induced-nephrotic-syndrome-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.20330","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,10]]}}}